Cargando…

Systemic Toxicity Reported for CDK8/19 Inhibitors CCT251921 and MSC2530818 Is Not Due to Target Inhibition

CDK8/19 kinases, which mediate transcriptional reprogramming, have become an active target for cancer drug discovery. Several small-molecule CDK8/19 inhibitors showed in vivo efficacy and two have entered clinical trials, with no significant toxicities reported. However, Clarke et al. (eLife 2016; 5...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Mengqian, Li, Jing, Liang, Jiaxin, Thompson, Zanshé S., Kathrein, Katie, Broude, Eugenia V., Roninson, Igor B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6912361/
https://www.ncbi.nlm.nih.gov/pubmed/31717492
http://dx.doi.org/10.3390/cells8111413
_version_ 1783479437899071488
author Chen, Mengqian
Li, Jing
Liang, Jiaxin
Thompson, Zanshé S.
Kathrein, Katie
Broude, Eugenia V.
Roninson, Igor B.
author_facet Chen, Mengqian
Li, Jing
Liang, Jiaxin
Thompson, Zanshé S.
Kathrein, Katie
Broude, Eugenia V.
Roninson, Igor B.
author_sort Chen, Mengqian
collection PubMed
description CDK8/19 kinases, which mediate transcriptional reprogramming, have become an active target for cancer drug discovery. Several small-molecule CDK8/19 inhibitors showed in vivo efficacy and two have entered clinical trials, with no significant toxicities reported. However, Clarke et al. (eLife 2016; 5; e20722) found severe systemic toxicity associated with two potent CDK8/19 inhibitors, Cmpd3 (CCT251921) and Cmpd4 (MSC2530818), and suggested that their toxicity was due to on-target effects. Here, we compared five CDK8/19 inhibitors: Cmpd3, Cmpd4, Senexin B, 16-didehydro-cortistatin A (dCA) and 15w, in different assays. Only Cmpd4 showed striking toxicity in developing zebrafish. In cell-based assays for CDK8 and CDK19 inhibition, Cmpd3, Cmpd4, dCA and 15w showed similar low-nanomolar potency and efficacy against CDK8 and CDK19, while Senexin B was less potent. Only dCA produced sustained inhibition of CDK8/19-dependent gene expression. While toxicity of different compounds did not correlate with their effects on CDK8 and CDK19, kinome profiling identified several off-target kinases for both Cmpd3 and Cmpd4, which could be responsible for their toxicity. Off-target activities could have been achieved in the study of Clarke et al. due to high in vivo doses of Cmpd3 and Cmpd4, chosen for the ability to inhibit STAT1 S727 phosphorylation in tumor xenografts. We show here that STAT1 S727 phosphorylation is induced by various cytokines and stress stimuli in CDK8/19-independent manner, indicating that it is not a reliable pharmacodynamic marker of CDK8/19 activity. These results illustrate the need for careful off-target analysis and dose selection in the development of CDK8/19 inhibitors.
format Online
Article
Text
id pubmed-6912361
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-69123612020-01-02 Systemic Toxicity Reported for CDK8/19 Inhibitors CCT251921 and MSC2530818 Is Not Due to Target Inhibition Chen, Mengqian Li, Jing Liang, Jiaxin Thompson, Zanshé S. Kathrein, Katie Broude, Eugenia V. Roninson, Igor B. Cells Article CDK8/19 kinases, which mediate transcriptional reprogramming, have become an active target for cancer drug discovery. Several small-molecule CDK8/19 inhibitors showed in vivo efficacy and two have entered clinical trials, with no significant toxicities reported. However, Clarke et al. (eLife 2016; 5; e20722) found severe systemic toxicity associated with two potent CDK8/19 inhibitors, Cmpd3 (CCT251921) and Cmpd4 (MSC2530818), and suggested that their toxicity was due to on-target effects. Here, we compared five CDK8/19 inhibitors: Cmpd3, Cmpd4, Senexin B, 16-didehydro-cortistatin A (dCA) and 15w, in different assays. Only Cmpd4 showed striking toxicity in developing zebrafish. In cell-based assays for CDK8 and CDK19 inhibition, Cmpd3, Cmpd4, dCA and 15w showed similar low-nanomolar potency and efficacy against CDK8 and CDK19, while Senexin B was less potent. Only dCA produced sustained inhibition of CDK8/19-dependent gene expression. While toxicity of different compounds did not correlate with their effects on CDK8 and CDK19, kinome profiling identified several off-target kinases for both Cmpd3 and Cmpd4, which could be responsible for their toxicity. Off-target activities could have been achieved in the study of Clarke et al. due to high in vivo doses of Cmpd3 and Cmpd4, chosen for the ability to inhibit STAT1 S727 phosphorylation in tumor xenografts. We show here that STAT1 S727 phosphorylation is induced by various cytokines and stress stimuli in CDK8/19-independent manner, indicating that it is not a reliable pharmacodynamic marker of CDK8/19 activity. These results illustrate the need for careful off-target analysis and dose selection in the development of CDK8/19 inhibitors. MDPI 2019-11-09 /pmc/articles/PMC6912361/ /pubmed/31717492 http://dx.doi.org/10.3390/cells8111413 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Chen, Mengqian
Li, Jing
Liang, Jiaxin
Thompson, Zanshé S.
Kathrein, Katie
Broude, Eugenia V.
Roninson, Igor B.
Systemic Toxicity Reported for CDK8/19 Inhibitors CCT251921 and MSC2530818 Is Not Due to Target Inhibition
title Systemic Toxicity Reported for CDK8/19 Inhibitors CCT251921 and MSC2530818 Is Not Due to Target Inhibition
title_full Systemic Toxicity Reported for CDK8/19 Inhibitors CCT251921 and MSC2530818 Is Not Due to Target Inhibition
title_fullStr Systemic Toxicity Reported for CDK8/19 Inhibitors CCT251921 and MSC2530818 Is Not Due to Target Inhibition
title_full_unstemmed Systemic Toxicity Reported for CDK8/19 Inhibitors CCT251921 and MSC2530818 Is Not Due to Target Inhibition
title_short Systemic Toxicity Reported for CDK8/19 Inhibitors CCT251921 and MSC2530818 Is Not Due to Target Inhibition
title_sort systemic toxicity reported for cdk8/19 inhibitors cct251921 and msc2530818 is not due to target inhibition
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6912361/
https://www.ncbi.nlm.nih.gov/pubmed/31717492
http://dx.doi.org/10.3390/cells8111413
work_keys_str_mv AT chenmengqian systemictoxicityreportedforcdk819inhibitorscct251921andmsc2530818isnotduetotargetinhibition
AT lijing systemictoxicityreportedforcdk819inhibitorscct251921andmsc2530818isnotduetotargetinhibition
AT liangjiaxin systemictoxicityreportedforcdk819inhibitorscct251921andmsc2530818isnotduetotargetinhibition
AT thompsonzanshes systemictoxicityreportedforcdk819inhibitorscct251921andmsc2530818isnotduetotargetinhibition
AT kathreinkatie systemictoxicityreportedforcdk819inhibitorscct251921andmsc2530818isnotduetotargetinhibition
AT broudeeugeniav systemictoxicityreportedforcdk819inhibitorscct251921andmsc2530818isnotduetotargetinhibition
AT roninsonigorb systemictoxicityreportedforcdk819inhibitorscct251921andmsc2530818isnotduetotargetinhibition